Boston Scientific Corporation (NYSE:BSX)宣布恢复其AVANT GUARD临床试验,该试验针对一组新的持续性心房颤动未经药物治疗的患者。此前该试验因需要评估观察结果而暂停,但经过仔细审查并与研究数据监测委员会协商后,试验招募将继续进行。 AVANT GUARD试验是Boston Scientific的一项重要研究,该公司以开发和生产用于介入医学专科的医疗器械而 ...

Wednesday, October 30, 2024 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including ...

On Wednesday, Boston Scientific Corporation (NYSE:BSX) released the results of the primary endpoint of the ACURATE IDE trial of ACURATE neo2 Aortic Valve System for patients with severe ...

Boston Scientific continues to work closely with the U.S. Food and Drug Administration on the regulatory strategy for approval of the ACURATE valve platform in the U.S. The ACURATE neo2 Aortic ...

“What’s your favourite scary movie?” Ghostface repeatedly asks his victims. Well, that’s a matter of preference, but if you (and possibly whoever’s donning the Scream franchise disguise ...

Boston Scientific Corporation (NYSE ... and data from the US ACURATE IDE will be presented at TCT on October 30. WATCHMAN ...

“Use of these data therefore not only spreads disinformation but also helps the political project of scientific racism—the misuse of science to promote the idea that racial hierarchies and ...

Peripheral Intervention Sales Growth: 10% organically in Q3 2024. Neurology Sales Growth: 10% in Q3 2024. Endoscopy Sales Growth: 7% organically in Q3 2024. Boston Scientific Corp (NYSE:BSX) reported ...

Boston Scientific Corporation reported 19.3% y/y ... Regulatory approvals and trials, particularly for WATCHMAN FLX Pro and FARAPULSE, are crucial for future performance and could introduce ...

“Globally, we surpassed 500,000 patients treated with a Watchman device driven by our innovation, clinical evidence and patient-awareness efforts,” Mahoney said. Boston Scientific’s business ...